abstract |
Compounds of formula (I)n nwherein R 1 , HET-1 and HET-2 are as described in the specification, nand their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described. |